A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus

por Doria, A, Bass, D, Schwarting, A, Hammer, A, Gordon, D, Scheinberg, M, Fox, N L, Groark, J, Stohl, W, Kleoudis, C, Roth, D
Publicado 2018

Efficacy and Safety of Subcutaneous Belimumab in Anti–Double‐Stranded DNA–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus

por Doria, A., Stohl, W., Schwarting, A., Okada, M., Scheinberg, M., van Vollenhoven, R., Hammer, A. E., Groark, J., Bass, D., Fox, N. L., Roth, D., Gordon, D.
Publicado 2018

A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma

por Younes, A, Vose, J M, Zelenetz, A D, Smith, M R, Burris, H A, Ansell, S M, Klein, J, Halpern, W, Miceli, R, Kumm, E, Fox, N L, Czuczman, M S
Publicado 2010